Multiple Myeloma
Showing 1 - 25 of >10,000
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,
Recruiting
- High-risk Smoldering Multiple Myeloma
- +2 more
- Teclistamab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Aug 11, 2022
Health Technology Intervention on Patient Activation in Multiple
Not yet recruiting
- Multiple Myeloma in Relapse
- +3 more
- (no location specified)
Jan 9, 2023
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Rapid Infusion Isatuximab
- (no location specified)
Jul 3, 2022
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Aug 8, 2022
Two Biologically and Clinically Distinct Entities: Progressive
Recruiting
- Multiple Myeloma
- +2 more
-
Miami, FloridaUniversity of Miami Hospitals
Jun 7, 2022
Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)
Not yet recruiting
- Multiple Myeloma
- CART-ddBCMA
-
Boston, Massachusetts
- +1 more
Jul 7, 2022
Host Microbiota and Il-17 in Favoring Multiple Myeloma
Recruiting
- Multiple Myeloma
-
Milan, Milano, ItalyIRCCS Ospedale San Raffaele
Jan 26, 2023
Selinexor, Daratumumab and Dexamethasone in Chinese Multiple
Not yet recruiting
- Multiple Myeloma at First Relapse
- (no location specified)
Sep 27, 2022
Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)
Recruiting
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
- BCMA Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022
Using Mass Spectrometry Detecting Minimal Residual Disease in
Recruiting
- Multiple Myeloma
-
Tianjin, ChinaInsituteHBDH
Sep 8, 2022
Based on Maintenance Therapy Post Autologous Stem Cell
Recruiting
- Multiple Myeloma
- Autologous Stem Cell Transplant
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jul 27, 2022
Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 15, 2022
Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))
Withdrawn
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- (no location specified)
Apr 27, 2022
Serum NGAL IN Patients With Multiple Myeloma
Not yet recruiting
- Multiple Myeloma(MM)
- SERUM NGAL
- (no location specified)
Jun 26, 2022
Multiple Myeloma Trial in Philadelphia (Coordinated Financial Navigation Program)
Recruiting
- Multiple Myeloma
- Coordinated Financial Navigation Program
-
Philadelphia, PennsylvaniaPenn Medicine
Jul 12, 2022
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Pembrolizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 23, 2022
Multiple Myeloma Trial (Cilta-cel OOS Therapy)
Available
- Multiple Myeloma
- Cilta-cel OOS Therapy
- (no location specified)
Aug 15, 2022
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Thrombosis in Multiple Myeloma in an University Medical Center
Recruiting
- Multiple Myeloma
- +2 more
- Multiple myeloma
-
Groningen, NetherlandsUniversity Medical Center Groningen
Sep 12, 2022
Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)
Recruiting
- Multiple Myeloma
- New Diagnosis Tumor
- BCMA CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)
Recruiting
- Multiple Myeloma
- +2 more
- MCARH125
- MCARH109
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jun 20, 2022
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023